CMA
CPRX

Cedar Mountain Advisors’s Catalyst Pharmaceutical CPRX Stock Holding History

Cedar Mountain Advisors’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$157 Hold
5
– – ﹤0.01% 1141
2026
Q1 		$124 Buy
+5
New +$119 ﹤0.01% 1114

Other funds holding CPRX

Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
LTAS
Linden Thomas Advisory Services Charlotte, North Carolina $1.24B AUM 47.37% 1-Year Est. Return
COPPSERS
Commonwealth of Pennsylvania Public School Employees Retirement System Harrisburg, Pennsylvania $20.6B AUM 37.37% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
RA
RFG Advisory Birmingham, Alabama $6.4B AUM 19.93% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
EWM
Empirical Wealth Management Seattle, Washington $6.85B AUM 30.02% 1-Year Est. Return
OLA
Oliver Luxxe Assets Gladstone, New Jersey $680M AUM 47.51% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

Cedar Mountain Advisors's CPRX Position: Q2 2026 in Review

Cedar Mountain Advisors held its Catalyst Pharmaceutical (CPRX) position steady in Q2 2026 at 5 shares worth $157. The position accounts for ﹤0.01% of the portfolio, ranked #1141.

Cedar Mountain Advisors first reported a position in CPRX in Q1 2026 and has held it in 2 quarters since. 36 funds tracked by Wall St. Rank hold CPRX as of Q2 2026.

  • Cedar Mountain Advisors held 5 shares of Catalyst Pharmaceutical worth $157 as of Q2 2026.
  • Cedar Mountain Advisors left its Catalyst Pharmaceutical share count unchanged in Q2 2026.
  • Catalyst Pharmaceutical made up ﹤0.01% of Cedar Mountain Advisors's portfolio in Q2 2026, its #1141 holding.
  • Cedar Mountain Advisors first reported a position in Catalyst Pharmaceutical in Q1 2026 and has held it in 2 quarters since.
  • 36 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2026.

Based on Cedar Mountain Advisors's 13F filing for Q2 2026, filed 2 Jul 2026.